Karen Tsai

Cooley advised CalypsoAI, an adaptive artificial intelligence security platform that empowers enterprises to innovate safely, on its acquisition by F5, a global leader in delivering and securing every app and application programming interface.

Cooley advised Infleqtion, a global leader in neutral atom-based quantum technology, on its definitive business combination agreement with Churchill Capital Corp X, with the aim to accelerate Infleqtion’s mission to commercialize quantum products that provide orders of magnitude improvement in computing and precision sensing applications.

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential.

Cooley advised CHARM Therapeutics, a biotechnology company pioneering the next generation of precision oncology treatments through its proprietary artificial intelligence-driven drug discovery platform, on its $80 million Series B financing, to advance its next-generation menin inhibitor into clinical development.

Cooley advised Indian conglomerate Reliance Industries on its joint venture with Meta that will build and scale enterprise artificial intelligence solutions for enterprises in India and select international markets.